Click here to get full coverage on Akari Initiates Manufacturing Activities to Support AKTX-101 Development - Contract Pharma

Akari Initiates Manufacturing Activities to Support AKTX-101 Development  Contract Pharma

Akari Initiates Manufacturing Activities to Support AKTX-101 Development - Contract Pharma

Click here to get full coverage on Volatility Watch: Is AKTX attractive for institutional investors - Weekly Trade Summary & Long Hold Capital Preservation Tips - baoquankhu1.vn

Volatility Watch: Is AKTX attractive for institutional investors - Weekly Trade Summary & Long Hold Capital Preservation Tips  baoquankhu1.vn

Volatility Watch: Is AKTX attractive for institutional investors - Weekly Trade Summary & Long Hold Capital Preservation Tips - baoquankhu1.vn

Click here to get full coverage on Inside a biotech’s new cancer approach now planning first human trials in 2026 - Stock Titan

Inside a biotech’s new cancer approach now planning first human trials in 2026  Stock Titan

Inside a biotech’s new cancer approach now planning first human trials in 2026 - Stock Titan

Click here to get full coverage on Akari’s AKTX-101 shows potential for KRAS-mutant PDAC - BioWorld MedTech

Akari’s AKTX-101 shows potential for KRAS-mutant PDAC  BioWorld MedTech

Akari’s AKTX-101 shows potential for KRAS-mutant PDAC - BioWorld MedTech

Click here to get full coverage on Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial - Yahoo Finance

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial  Yahoo Finance

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial - Yahoo Finance

Click here to get full coverage on $AKTX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

$AKTX stock is down 17% today. Here's what we see in our data.  Quiver Quantitative

$AKTX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Akari Therapeutics CEO says company progressing to critical inflection points - MSN

Akari Therapeutics CEO says company progressing to critical inflection points  MSN

Akari Therapeutics CEO says company progressing to critical inflection points - MSN

Click here to get full coverage on Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - simplywall.st

Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m  simplywall.st

Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - simplywall.st

Click here to get full coverage on CGTX, RVPH, SHOT, SONN, AKTX Rally After-Hours On Clinical Updates And Fed Rate Cut Momentum - Nasdaq

CGTX, RVPH, SHOT, SONN, AKTX Rally After-Hours On Clinical Updates And Fed Rate Cut Momentum  Nasdaq

CGTX, RVPH, SHOT, SONN, AKTX Rally After-Hours On Clinical Updates And Fed Rate Cut Momentum - Nasdaq

Click here to get full coverage on Is AKTX gaining market share - July 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru

Is AKTX gaining market share - July 2025 Weekly Recap & Long Hold Capital Preservation Plans  mfd.ru

Is AKTX gaining market share - July 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru

Click here to get full coverage on Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm

Akari Therapeutics to Present at the 2026 Biotech Showcase  Sahm

Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm

Click here to get full coverage on Portfolio Update: Is AKTX showing insider buying - Market Activity Report & Scalable Portfolio Growth Methods - baoquankhu1.vn

Portfolio Update: Is AKTX showing insider buying - Market Activity Report & Scalable Portfolio Growth Methods  baoquankhu1.vn

Portfolio Update: Is AKTX showing insider buying - Market Activity Report & Scalable Portfolio Growth Methods - baoquankhu1.vn

Click here to get full coverage on Akari Therapeutics (NASDAQ: AKTX) prices $5M ADS deal, $2.5M debt swap - Stock Titan

Akari Therapeutics (NASDAQ: AKTX) prices $5M ADS deal, $2.5M debt swap  Stock Titan

Akari Therapeutics (NASDAQ: AKTX) prices $5M ADS deal, $2.5M debt swap - Stock Titan

Click here to get full coverage on Akari Therapeutics Announces Promising Preclinical Data for AKTX-101 Targeting K-Ras G12V Mutated Pancreatic Cancer - Quiver Quantitative

Akari Therapeutics Announces Promising Preclinical Data for AKTX-101 Targeting K-Ras G12V Mutated Pancreatic Cancer  Quiver Quantitative

Akari Therapeutics Announces Promising Preclinical Data for AKTX-101 Targeting K-Ras G12V Mutated Pancreatic Cancer - Quiver Quantitative

Click here to get full coverage on $AKTX stock is up 51% today. Here's what we see in our data. - Quiver Quantitative

$AKTX stock is up 51% today. Here's what we see in our data.  Quiver Quantitative

$AKTX stock is up 51% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Akari Therapeutics (Nasdaq: AKTX) CEO Corner Highlights ADC Payload and Platform - Stock Titan

Akari Therapeutics (Nasdaq: AKTX) CEO Corner Highlights ADC Payload and Platform  Stock Titan

Akari Therapeutics (Nasdaq: AKTX) CEO Corner Highlights ADC Payload and Platform - Stock Titan

Click here to get full coverage on Akari Therapeutics CEO to Present at 2026 Biotech Showcase on ADC Platform and Strategic Milestones - Quiver Quantitative

Akari Therapeutics CEO to Present at 2026 Biotech Showcase on ADC Platform and Strategic Milestones  Quiver Quantitative

Akari Therapeutics CEO to Present at 2026 Biotech Showcase on ADC Platform and Strategic Milestones - Quiver Quantitative

Click here to get full coverage on Akari Therapeutics CEO Discusses Innovative ADC Development and Future Clinical Trials in Virtual Investor Segment - Quiver Quantitative

Akari Therapeutics CEO Discusses Innovative ADC Development and Future Clinical Trials in Virtual Investor Segment  Quiver Quantitative

Akari Therapeutics CEO Discusses Innovative ADC Development and Future Clinical Trials in Virtual Investor Segment - Quiver Quantitative

Click here to get full coverage on Akari Therapeutics Announces $5 Million Financing Through ADS Offering and Warrants | AKTX Stock News - Quiver Quantitative

Akari Therapeutics Announces $5 Million Financing Through ADS Offering and Warrants | AKTX Stock News  Quiver Quantitative

Akari Therapeutics Announces $5 Million Financing Through ADS Offering and Warrants | AKTX Stock News - Quiver Quantitative

Click here to get full coverage on Akari Therapeutics Publishes CEO Corner Segment Highlighting Progress and Future Opportunities - Quiver Quantitative

Akari Therapeutics Publishes CEO Corner Segment Highlighting Progress and Future Opportunities  Quiver Quantitative

Akari Therapeutics Publishes CEO Corner Segment Highlighting Progress and Future Opportunities - Quiver Quantitative

Click here to get full coverage on New cancer-targeting drug moves toward first human tests after key step - Stock Titan

New cancer-targeting drug moves toward first human tests after key step  Stock Titan

New cancer-targeting drug moves toward first human tests after key step - Stock Titan

Click here to get full coverage on Akari Therapeutics (Nasdaq: AKTX) details PH1 ADC platform, targets 4Q 2026 trials - Stock Titan

Akari Therapeutics (Nasdaq: AKTX) details PH1 ADC platform, targets 4Q 2026 trials  Stock Titan

Akari Therapeutics (Nasdaq: AKTX) details PH1 ADC platform, targets 4Q 2026 trials - Stock Titan

Click here to get full coverage on Akari Therapeutics (Nasdaq: AKTX) unveils CEO Corner, interactive Q&A on ADC pipeline - Stock Titan

Akari Therapeutics (Nasdaq: AKTX) unveils CEO Corner, interactive Q&A on ADC pipeline  Stock Titan

Akari Therapeutics (Nasdaq: AKTX) unveils CEO Corner, interactive Q&A on ADC pipeline - Stock Titan

Click here to get full coverage on Akari (Nasdaq: AKTX) appoints Kameel Farag interim CFO with 20+ years in finance - Stock Titan

Akari (Nasdaq: AKTX) appoints Kameel Farag interim CFO with 20+ years in finance  Stock Titan

Akari (Nasdaq: AKTX) appoints Kameel Farag interim CFO with 20+ years in finance - Stock Titan

Click here to get full coverage on Akari Therapeutics to Present at the 2026 Biotech Showcase - Chartmill

Akari Therapeutics to Present at the 2026 Biotech Showcase  Chartmill

Akari Therapeutics to Present at the 2026 Biotech Showcase - Chartmill

Click here to get full coverage on AKTX: Akari Therapeutics Eyes Future Growth with Key Developments - GuruFocus

AKTX: Akari Therapeutics Eyes Future Growth with Key Developments  GuruFocus

AKTX: Akari Therapeutics Eyes Future Growth with Key Developments - GuruFocus

Click here to get full coverage on Akari Therapeutics shares climb after encouraging early data for pancreatic cancer candidate - MSN

Akari Therapeutics shares climb after encouraging early data for pancreatic cancer candidate  MSN

Akari Therapeutics shares climb after encouraging early data for pancreatic cancer candidate - MSN

Click here to get full coverage on Akari Therapeutics Issues 2025 End of Year Letter to Shareholders - Yahoo Finance

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders  Yahoo Finance

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders - Yahoo Finance

Click here to get full coverage on Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer - TradingView — Track All Markets

Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer  TradingView — Track All Markets

Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer - TradingView — Track All Markets

Click here to get full coverage on Akari Therapeutics Releases Virtual Investor “What This Means” Segment - GlobeNewswire

Akari Therapeutics Releases Virtual Investor “What This Means” Segment  GlobeNewswire

Akari Therapeutics Releases Virtual Investor “What This Means” Segment - GlobeNewswire

Click here to get full coverage on Akari Therapeutics secures $2.5 million through registered offering - Investing.com

Akari Therapeutics secures $2.5 million through registered offering  Investing.com

Akari Therapeutics secures $2.5 million through registered offering - Investing.com

Click here to get full coverage on Akari Therapeutics raises $5 million in at-market offering - Investing.com

Akari Therapeutics raises $5 million in at-market offering  Investing.com

Akari Therapeutics raises $5 million in at-market offering - Investing.com

Click here to get full coverage on Akari Therapeutics Publishes New CEO Corner Highlighting Advances in Antibody Drug Conjugates - Quiver Quantitative

Akari Therapeutics Publishes New CEO Corner Highlighting Advances in Antibody Drug Conjugates  Quiver Quantitative

Akari Therapeutics Publishes New CEO Corner Highlighting Advances in Antibody Drug Conjugates - Quiver Quantitative

Click here to get full coverage on Akari Therapeutics (AKTX) Announces New ADS and Warrant Issuance - GuruFocus

Akari Therapeutics (AKTX) Announces New ADS and Warrant Issuance  GuruFocus

Akari Therapeutics (AKTX) Announces New ADS and Warrant Issuance - GuruFocus

Click here to get full coverage on 12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session  Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Click here to get full coverage on Akari Therapeutics Prepares Investor Presentation for Conferences - TipRanks

Akari Therapeutics Prepares Investor Presentation for Conferences  TipRanks

Akari Therapeutics Prepares Investor Presentation for Conferences - TipRanks

Click here to get full coverage on Akari Therapeutics Insiders Added US$1.79m Of Stock To Their Holdings - Yahoo Finance

Akari Therapeutics Insiders Added US$1.79m Of Stock To Their Holdings  Yahoo Finance

Akari Therapeutics Insiders Added US$1.79m Of Stock To Their Holdings - Yahoo Finance

Click here to get full coverage on Akari Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Akari Therapeutics Faces Nasdaq Delisting Notice  TipRanks

Akari Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Click here to get full coverage on Akari appoints head of business development - oncology - The Pharma Letter

Akari appoints head of business development - oncology  The Pharma Letter

Akari appoints head of business development - oncology - The Pharma Letter

Click here to get full coverage on Akari Therapeutics advances ADC oncology program with novel payload - Investing.com

Akari Therapeutics advances ADC oncology program with novel payload  Investing.com

Akari Therapeutics advances ADC oncology program with novel payload - Investing.com

Click here to get full coverage on 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session  Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Click here to get full coverage on Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com

Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com  Investing.com

Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com

Click here to get full coverage on Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com

Akari Therapeutics appoints Kameel Farag as interim CFO  Investing.com

Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com

Click here to get full coverage on Akari Therapeutics Approves Key Resolutions at Meeting - TipRanks

Akari Therapeutics Approves Key Resolutions at Meeting  TipRanks

Akari Therapeutics Approves Key Resolutions at Meeting - TipRanks

Click here to get full coverage on Akari Therapeutics files two new patents with USPTO - Yahoo Finance

Akari Therapeutics files two new patents with USPTO  Yahoo Finance

Akari Therapeutics files two new patents with USPTO - Yahoo Finance

Click here to get full coverage on Akari Therapeutics working to advance lead asset, find other targets - BioWorld MedTech

Akari Therapeutics working to advance lead asset, find other targets  BioWorld MedTech

Akari Therapeutics working to advance lead asset, find other targets - BioWorld MedTech

Click here to get full coverage on Akari Therapeutics Announces Launch of CEO Corner Platform - Yahoo Finance

Akari Therapeutics Announces Launch of CEO Corner Platform  Yahoo Finance

Akari Therapeutics Announces Launch of CEO Corner Platform - Yahoo Finance

Click here to get full coverage on Akari begins GMP manufacturing of lead ADC program with WuXi XDC - Investing.com

Akari begins GMP manufacturing of lead ADC program with WuXi XDC  Investing.com

Akari begins GMP manufacturing of lead ADC program with WuXi XDC - Investing.com

Click here to get full coverage on Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com Canada

Akari Therapeutics raises $5 million in at-market offering By Investing.com  Investing.com Canada

Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com Canada

Click here to get full coverage on Akari Therapeutics Announces Release of the Next CEO Corner Segment - Yahoo Finance

Akari Therapeutics Announces Release of the Next CEO Corner Segment  Yahoo Finance

Akari Therapeutics Announces Release of the Next CEO Corner Segment - Yahoo Finance

Click here to get full coverage on Akari Advances Towards First-in-Human Trial With Novel ADC Payload - Nasdaq

Akari Advances Towards First-in-Human Trial With Novel ADC Payload  Nasdaq

Akari Advances Towards First-in-Human Trial With Novel ADC Payload - Nasdaq

Click here to get full coverage on Akari Therapeutics Announces $5M Financing Agreement - TipRanks

Akari Therapeutics Announces $5M Financing Agreement  TipRanks

Akari Therapeutics Announces $5M Financing Agreement - TipRanks

Click here to get full coverage on Akari Therapeutics launches $2.5 million registered direct offering - MSN

Akari Therapeutics launches $2.5 million registered direct offering  MSN

Akari Therapeutics launches $2.5 million registered direct offering - MSN

Click here to get full coverage on Akari Therapeutics CEO says company ‘progressing to critical inflection points’ - TipRanks

Akari Therapeutics CEO says company ‘progressing to critical inflection points’  TipRanks

Akari Therapeutics CEO says company ‘progressing to critical inflection points’ - TipRanks

Click here to get full coverage on Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance - Investing.com

Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance  Investing.com

Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance - Investing.com

Click here to get full coverage on Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket  Benzinga

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga

Click here to get full coverage on Published on: 2026-01-20 09:20:28 - baoquankhu1.vn

Published on: 2026-01-20 09:20:28  baoquankhu1.vn

Published on: 2026-01-20 09:20:28 - baoquankhu1.vn

Click here to get full coverage on Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com Nigeria

Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com  Investing.com Nigeria

Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com Nigeria

Click here to get full coverage on Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com India

Akari Therapeutics raises $5 million in at-market offering By Investing.com  Investing.com India

Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com India

Click here to get full coverage on Akari Therapeutics Appoints Abizer Gaslightwala as CEO - citybiz

Akari Therapeutics Appoints Abizer Gaslightwala as CEO  citybiz

Akari Therapeutics Appoints Abizer Gaslightwala as CEO - citybiz

Click here to get full coverage on Akari Therapeutics Plc (AKTX) reports earnings - qz.com

Akari Therapeutics Plc (AKTX) reports earnings  qz.com

Akari Therapeutics Plc (AKTX) reports earnings - qz.com

Click here to get full coverage on Whittier Daily News - FinancialContent

Whittier Daily News - FinancialContent

Click here to get full coverage on Dow Theory Letters - AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders - FinancialContent

Dow Theory Letters - AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders  FinancialContent

Dow Theory Letters - AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders - FinancialContent

Click here to get full coverage on Daily Breeze - FinancialContent

Daily Breeze - FinancialContent

Click here to get full coverage on Akari Therapeutics Appoints Melissa Bradford-Klug as COO - citybiz

Akari Therapeutics Appoints Melissa Bradford-Klug as COO  citybiz

Akari Therapeutics Appoints Melissa Bradford-Klug as COO - citybiz

Click here to get full coverage on Akari Therapeutics (AKTX) - Zacks Investment Research

Akari Therapeutics (AKTX)  Zacks Investment Research

Akari Therapeutics (AKTX) - Zacks Investment Research

Click here to get full coverage on Akari Therapeutics (AKTX) Stock Price, News & Analysis - MarketBeat

Akari Therapeutics (AKTX) Stock Price, News & Analysis  MarketBeat

Akari Therapeutics (AKTX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Akari Therapeutics Appoints Michael Grissinger and Dr. Peter Feldschreiber to Board - newyork.citybuzz.co

Akari Therapeutics Appoints Michael Grissinger and Dr. Peter Feldschreiber to Board  newyork.citybuzz.co

AKTX

Price Chart

Key Statistics

Technicals

About AKTX

Latest News

Akari Initiates Manufacturing Activities to Support AKTX-101 Development - Contract Pharma

Volatility Watch: Is AKTX attractive for institutional investors - Weekly Trade Summary & Long Hold Capital Preservation Tips - baoquankhu1.vn

Inside a biotech’s new cancer approach now planning first human trials in 2026 - Stock Titan

Advanced Charts

Top Gainers

Top Losers